Lung cancer Cancer Malignant neoplasm of bronchus and lung
Conditions
Interventions
RAPID-RT has been designed to be as inclusive as possible. All patients over the age of 18 with stage I, II or III lung cancer who are undergoing curative-intent non-stereotactic ablative radiotherapy
Sponsors
Christie Hospital NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with stage I, II or III lung cancer (any type) 2. Undergoing curative-intent non-SABR radiotherapy at The Christie Hospital
Exclusion criteria
Exclusion criteria: 1. Under 18 years of age 2. Patients’ data will be excluded from this study if the patient opts out of the study 3. There are no exclusion criteria relating to patient comorbidities, any upper age limit or any other measure
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of the suitability of real-world data collected in the electronic health care record for patients with lung cancer at the Christie Hospital to evaluate changes in radiotherapy practice during the course of the study | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 03/04/2024: 1. Real-world treatment and outcome data extracted from eligible patient clinical notes in pseudo-anonymised form for modelling daily over the course of the study. 2. Quality of real-world data captured in the database (accuracy and completeness) analysed using data curation strategies at monthly intervals over the course of the study. 3. Assessment of changes in patients’ outcomes (1-year survival and incidence of grade 3+ oesophagitis or pneumonitis toxicities) following a change in standard of care radiotherapy that initially includes the addition of a dose limit for the top of the heart, assessed using developed statistical methodology as a continual process over course of the study 4. Review of opt-out consent implementation and percentage of patients who decline to include their data in the study at regular intervals over the course of the study. Interviews with patients and the clinical team will be used to look at acceptability of opt-out process. _____ Previous secondary outcome measures: 1. Real-world treatment and outcome data extracted from eligible patient clinical notes in pseudo-anonymised form for modelling daily over the course of the study. 2. Quality of real-world data captured in the database (accuracy and completeness) analysed using data curation strategies at monthly intervals over the course of the study. 3. Assessment of changes in patients’ outcomes (1-year survival and incidence of grade 3+ oesophagitis or pneumonitis toxicities) following a change in standard of care radiotherapy that initially includes the addition of a dose limit for the top of the heart, assessed using developed statistical methodology as a continual process over course of the study 4. Review of opt-out consent implementation and percentage of patients who decline to include their data in the study at regular intervals over the course of the study | — |
Countries
England, United Kingdom
Outcome results
None listed